Cardiology

End stage kidney disease

Questions discussed in this category

Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?

1 Answer available

For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?

1 Answer available

Should CT coronary calcium score be avoided in dialysis patients in light of presumed high prevalence of CAC in this population?

3 Answers available

Do you recommend continuing SGLT2 inhibitors in patients with diabetic kidney disease and congestive heart failure who have been taking the medication for several years and later develop end stage kidney disease?

3 Answers available

Papers discussed in this category

The New England journal of medicine, 2015 Sep 17

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

The New England journal of medicine, 2020 Sep 24

Dapagliflozin in Patients with Chronic Kidney Disease.

The New England journal of medicine, 2014-09-11

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Circulation, 2022 Apr 01

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

The New England journal of medicine, 2019 Sep 19

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

The New England journal of medicine, 2020 Aug 28

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Related Topics in Cardiology